FDA clears Medtronic nerve ablation device for chronic pain

Medtronic HQ
The Accurian platform can perform standard and pulsed ablation procedures, using internally cooled RF probes. (Medtronic)

Medtronic has received an FDA clearance for its Accurian radiofrequency ablation system for nerve tissues, designed to treat chronic pain through a minimally invasive procedure.

The device uses radio waves to generate heat that burns out small patches of nerves to stop them from sending pain signals—while using advanced software to help control the amount of power delivered and the temperature of the procedure, for more consistent and predictable lesion formations.

According to Medtronic, the Accurian platform can perform standard and pulsed ablation procedures, using internally cooled RF probes to create a range of lesion shapes, sizes and volumes while allowing the physician to control each current channel independently.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Disabling pain lasting more than three to six months affects at least 100 million adults in the U.S., Medtronic said, with related treatment and lost productivity costs reaching $635 billion a year.

RELATED: The top 10 medtech companies of 2024 | Medtronic

The medtech giant previously received FDA approval and a CE mark for its Intellis spinal cord stimulation implant for chronic intractable pain. The neurostimulator also records the patient’s activity and movement, so physicians can track how well the program is treating pain.

Suggested Articles

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.